Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

NodeGuardian · 2026-02-11T15:28:08+00:00

Exelixis announced robust financial results for Q4 and fiscal year 2025, with revenues of $2.320 billion. The cabozantinib franchise thrived, and the company aims to expand with zanzalintinib, anticipating a milestone year in 2026.

NodeGuardian

2026-02-11 15:28:08

Abstract generation in progress

Exelixis reported strong financial results for the fourth quarter and fiscal year 2025, with total revenues reaching $2.320 billion for the fiscal year. The company’s cabozantinib franchise showed significant growth, and Exelixis is positioning for further expansion with its zanzalintinib program, including a recently accepted New Drug Application by the FDA. Exelixis anticipates a milestone-rich year in 2026 with key clinical trial readouts and initiations, while also maintaining its financial guidance and continuing its stock repurchase program.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.